Global Antibiotic Resistance Partnership

The Global Antibiotic Resistance Partnership (GARP) was started in 2009 to create a platform for developing actionable policy proposals on antibiotic resistance in low-income and middle-income countries.

During the first three years, Phase 1 of GARP established national working groups in four countries: India, Kenya, South Africa and Vietnam.  Those working groups multidisciplinary, with representatives from all sectors, dealing with both human and animal antibiotic use have become national resources for their expertise and linkages to the current global activities in antibiotic resistance. 

GARP Phase 1 culminated in the 1st Global Forum on Bacterial Infections: Balancing Treatment Access and Antibiotic Resistance on October 3-5, 2011, in New Delhi, India. Since GARP Phase 2 began in 2012, national working groups have been established in Mozambique, Nepal, Tanzania and Uganda.

The GARP secretariat at the Center for Disease Dynamics, Economics & Policy (CDDEP), in Washington, DC and New Delhi, provides technical support to each working group, creates links within the GARP network and involves the working groups in global discussions and policy development.

GARP is a CDDEP project, funded by the Bill & Melinda Gates Foundation.



The bimonthly Global Antibiotic Resistance Partnership (GARP) Newsletter, GARPNet News, covers work being done around the world by the Global Antibiotic Resistance Partnership; sign up to receive...

O grupo tinha como objectivos:

1. Avaliar o ponto de situação sobre o



In his preface to the GARP-Tanzania Situation Analysis and Recommendations on Antibiotic Resistance in Tanzania, Professor Said Aboud, Chairman of the GARP-Tanzania Working...

CDDEP Senior Research Analyst Molly Miller-Petrie recently spoke with Dr. David Mutekanga, Principal Investigator of the Global Antibiotic Resistance Partnership (GARP)-...
CDDEP recently spoke with Eveline Wesangula, coordinator of the Global Antibiotic Resistance Partnership (GARP)-Kenya, about the GARP-Kenya working group’s progress...
GARP-South Africa recently achieved a major success with the approval and publication of the National Strategy for Antimicrobial Resistance (AMR). During a recent...
CDDEP recently spoke with Eveline Wesangula, coordinator of the Global Antibiotic Resistance Partnership (GARP)-Kenya, about GARP-Kenya’s group’s second antibiotic



In his presentation at TEDMED 2014, CDDEP Director Ramanan Laxminarayan spoke about approaching antibiotic resistance as a natural resource. He contends that we can learn from the field of energy conservation, and use dual strategies of conservation and innovation to preserve antibiotic effectiveness. To learn more about TEDMED and the 2014 event, visit the TEDMED website.
This infographic shows the burden of antibiotic resistance in the the one million children who die within the first four weeks of life each year in India.  Of these deaths, approximately 190,000 are caused by sepsis, a bacterial infection that overwhelms the bloodstream.  It's estimated that nearly one-third of these sepsis deaths are attributable to antibiotic resistance.
E. coli lives commensally in the gut, but pathogenic strains are also a leading cause of urinary tract infections (UTIs).  This graphic, adapted from a 2009 WHO report, shows percentages of E. coli samples resistant to ciprofloxacin, a fluoroquinolone antibiotic.
Extended spectrum beta-lactamase (ESBL)-producing gram-negative bacteria are multi-drug resistant and prevalent worldwide, particularly in hospital settings.  In developing countries there may be even fewer antibiotics available to treat infections caused by ESBL gram-negative pathogens.
Extended-spectrum macrolide sales are generally increasing in developing countries, and extended-spectrum macrolide antibiotics remain a high proportion of total macrolide use in the United States.  Why are the extended-spectrum drugs so popular in the U.S.?  Although overall antibiotic use in the U.S.